MedTrace Logo

Fosfomycin I.v. for Treatment of Severely Infected Patients

NCT02979951 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-10-01

No results posted yet for this study

Summary

The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.

Conditions

  • Bacterial Infections
  • Bone Diseases, Infectious
  • Osteomyelitis
  • Central Nervous System Bacterial Infections
  • Meningitis, Bacterial
  • Encephalitis
  • Brain Abscess
  • Urinary Tract Infections
  • Respiratory Tract Infections
  • Pneumonia, Bacterial
  • Skin Diseases, Bacterial
  • Soft Tissue Infections
  • Intraabdominal Infections
  • Sepsis
  • Bacteremia
  • Endocarditis, Bacterial

Sponsors & Collaborators

  • INPADS GmbH

    collaborator UNKNOWN

  • Dr. Oestreich + Partner GmbH

    collaborator UNKNOWN

  • Infectopharm Arzneimittel GmbH

    lead INDUSTRY

Principal Investigators

  • Klaus-Friedrich Bodmann, Dr. · Klinik Nordoberpfalz AG, Klinikum Weiden

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Austria
  • Germany
  • Greece
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02979951 on ClinicalTrials.gov